Summary of significant transactions - Gilead Collaboration Agreement (Details) $ in Millions |
12 Months Ended | |||||
|---|---|---|---|---|---|---|
|
Jan. 08, 2025
item
|
Aug. 23, 2019
EUR (€)
|
Aug. 23, 2019
USD ($)
|
Dec. 31, 2025
EUR (€)
item
|
Aug. 23, 2019
USD ($)
|
Jul. 14, 2019 |
|
| Spin-off | ||||||
| Summary Of Significant Transaction [line items] | ||||||
| Number Of Entities Following Spin Off | 2 | |||||
| Gilead collaboration agreement | ||||||
| Summary Of Significant Transaction [line items] | ||||||
| Upfront Payment Received | € 3,569,800,000 | $ 3,950 | ||||
| Equity Investment from Gilead. | € 960,100,000 | $ 1,100 | ||||
| Number of Performance Obligations | 3 | |||||
| revenue released. | € | € 1,069,000,000 | |||||
| Gilead collaboration agreement | Filgotinib drug license | Original Agreement | Gilead | ||||||
| Summary Of Significant Transaction [line items] | ||||||
| Cost Share For Global Development Activities | 25.00% | |||||
| Gilead collaboration agreement | Filgotinib drug license | First Revised Agreement | Gilead | ||||||
| Summary Of Significant Transaction [line items] | ||||||
| Cost Share For Global Development Activities | 50.00% | |||||